Chemoradiotherapy, Gastrointestinal Cancer, Nutritional Status
Conditions
Brief summary
To assess the effectiveness of close and intense monitoring on nutritional status of gastrointestinal cancer patients during chemoradiotherapy (CRT), 500 CRT patients diagnosed with gastrointestinal system are going to be recruited into this prospective study. Patient-generated subjective global assessment (PG-SGA) scale and nutrition risk screening (NRS-2002) are used for nutritional assessment at the beginning and the end of CRT; Beside the nutritional parameters, Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and gastric cancer module (QLQ-STO22) are used to measure quality of life in patients with gastric cancer while EORTC QLQ-C30 and Colorectal Cancer-Specific Quality of Life Questionnaire (QLQ-CR38) give assessment in colorectal cancer. The acute and late radiation toxicities were evaluated based on Conmon terminology criteria (CTC V3.0) and the toxicity criteria of RTOG/EORTC, respectively. Follow-ups every 3-6 months until three years after chemoradiotherapy are involved. Response Evaluation Criteria in Solid Tumors (RECIST) guidelines are used for response assessment. The primary endpoints are 3-year local control, disease-free survival, distant metastasis and overall survival rate.
Interventions
None listed
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Hubei Cancer Hospital
First Affiliated Hospital of Chongqing Medical University
Ruijin Hospital
Fudan University
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
for Gastric Cancer: * pathological confirmed adenocarcinoma * clinical stage T3-4 and/or N+ after radical surgery * without distance metastases * KPS \>=70 * without previous radiotherapy * sign the inform consent Inclusion Criteria for Rectal Cancer: * pathological confirmed adenocarcinoma * clinical stage T3-4 and/or N+ * the distance from anal verge less than 12 cm * without distance metastases * KPS \>=70 * without previous anti-cancer therapy * sign the inform consent
Exclusion criteria
* pregnancy or breast-feeding women * serious medical illness * baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/L, Hb≥90g/L, PLT≥100×10\^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN * DPD deficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local Control rate | From date of randomization until the date of first documented pelvic failure, assessed up to 3 years | Number of participants with abdominal or pelvic failure after surgery, evaluated using Kaplan-Meier Curve |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years |
| Overall Survival | From date of randomization until the date of death from any cause, assessed up to 3 years |
Countries
China
Outcome results
None listed